442 related articles for article (PubMed ID: 36091687)
1. Identification of N7-methylguanosine related signature for prognosis and immunotherapy efficacy prediction in lung adenocarcinoma.
Li Z; Wang W; Wu J; Ye X
Front Med (Lausanne); 2022; 9():962972. PubMed ID: 36091687
[TBL] [Abstract][Full Text] [Related]
2. Pan-cancer analysis identifies proteasome 26S subunit, ATPase (PSMC) family genes, and related signatures associated with prognosis, immune profile, and therapeutic response in lung adenocarcinoma.
Jia H; Tang WJ; Sun L; Wan C; Zhou Y; Shen WZ
Front Genet; 2022; 13():1017866. PubMed ID: 36699466
[No Abstract] [Full Text] [Related]
3. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosis.
Shu J; Jiang J; Zhao G
Front Immunol; 2023; 14():1177847. PubMed ID: 37583701
[TBL] [Abstract][Full Text] [Related]
5. A cuproptosis-related lncRNA signature for predicting prognosis and immunotherapy response of lung adenocarcinoma.
Yu S; Tang L; Zhang Q; Li W; Yao S; Cai Y; Cheng H
Hereditas; 2023 Jul; 160(1):31. PubMed ID: 37482612
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of the immunogenic cell death-related signature for predicting prognosis and immunotherapy efficiency in patients with lung adenocarcinoma.
Cui Y; Li Y; Long S; Xu Y; Liu X; Sun Z; Sun Y; Hu J; Li X
BMC Med Genomics; 2023 Aug; 16(1):184. PubMed ID: 37553698
[TBL] [Abstract][Full Text] [Related]
7. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
[TBL] [Abstract][Full Text] [Related]
8. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
Front Immunol; 2021; 12():693062. PubMed ID: 34497605
[TBL] [Abstract][Full Text] [Related]
9. Single-cell sequencing analysis and transcriptome analysis constructed the macrophage related gene-related signature in lung adenocarcinoma and verified by an independent cohort.
Li R; Tong R; Zhang Z; Deng M; Wang T; Hou G
Genomics; 2022 Nov; 114(6):110520. PubMed ID: 36372305
[TBL] [Abstract][Full Text] [Related]
10. Apoptosis-Related Signature Predicts Prognosis and Immune Microenvironment Infiltration in Lung Adenocarcinoma.
Zou X; He R; Zhang Z; Yan Y
Front Genet; 2022; 13():818403. PubMed ID: 35571020
[TBL] [Abstract][Full Text] [Related]
11. An ICD-Associated DAMP Gene signature predicts survival and immunotherapy response of patients with lung adenocarcinoma.
Wu Y; Li K; Liang S; Lou X; Li Y; Xu D; Wu Y; Wang Y; Cui W
Respir Res; 2023 May; 24(1):142. PubMed ID: 37259066
[TBL] [Abstract][Full Text] [Related]
12. Identification of natural killer cell associated subtyping and gene signature to predict prognosis and drug sensitivity of lung adenocarcinoma.
Zhang D; Zhao Y
Front Genet; 2023; 14():1156230. PubMed ID: 37091780
[No Abstract] [Full Text] [Related]
13. Development and validation of polyamines metabolism-associated gene signatures to predict prognosis and immunotherapy response in lung adenocarcinoma.
Wang N; Chai M; Zhu L; Liu J; Yu C; Huang X
Front Immunol; 2023; 14():1070953. PubMed ID: 37334367
[TBL] [Abstract][Full Text] [Related]
14. Identification of a novel m5C/m6A-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
Ma Y; Yang J; Ji T; Wen F
Front Genet; 2022; 13():990623. PubMed ID: 36246622
[TBL] [Abstract][Full Text] [Related]
15. Systematic Analysis and Identification of Molecular Subtypes of TRP-Related Genes and Prognosis Prediction in Lung Adenocarcinoma.
Guo Y; Liu N
J Oncol; 2022; 2022():5388283. PubMed ID: 36090899
[TBL] [Abstract][Full Text] [Related]
16. Identification of lung adenocarcinoma subtypes and a prognostic signature based on activity changes of the hallmark and immunologic gene sets.
Zhou SK; Zeng DH; Zhang MQ; Chen MM; Liu YM; Chen QQ; Lin ZY; Yang SS; Fu ZC; Lian DH; Ying WM
Heliyon; 2024 Apr; 10(7):e28090. PubMed ID: 38571596
[TBL] [Abstract][Full Text] [Related]
17. Characterization of polyamine metabolism predicts prognosis, immune profile, and therapeutic efficacy in lung adenocarcinoma patients.
Li Z; Wu Y; Yang W; Wang W; Li J; Huang X; Yang Y; Zhang X; Ye X
Front Cell Dev Biol; 2024; 12():1331759. PubMed ID: 38650895
[TBL] [Abstract][Full Text] [Related]
18. Molecular typing and prognostic model of lung adenocarcinoma based on cuprotosis-related lncRNAs.
Zheng M; Zhou H; Xie J; Zhang H; Shen X; Zhu D
J Thorac Dis; 2022 Dec; 14(12):4828-4845. PubMed ID: 36647499
[TBL] [Abstract][Full Text] [Related]
19. Development of a copper metabolism-related gene signature in lung adenocarcinoma.
Chang W; Li H; Zhong L; Zhu T; Chang Z; Ou W; Wang S
Front Immunol; 2022; 13():1040668. PubMed ID: 36524120
[TBL] [Abstract][Full Text] [Related]
20. Pan-cancer analysis of UBE2T with a focus on prognostic and immunological roles in lung adenocarcinoma.
Cao K; Ling X; Jiang X; Ma J; Zhu J
Respir Res; 2022 Nov; 23(1):306. PubMed ID: 36357897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]